RxDoctor Payments Data

Oluropo Ayeni, MD

Internal Medicine · Jonesboro, GANPI 1275572190

Payments from drug & device makers

$2,207in general payments, 2019–2025

Across 104 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$656
  • Novo Nordisk$322
  • Pfizer$212
  • Lilly USA, LLC$183
  • Novartis$157
  • Amgen$123
  • plus $552 from 14 others

What the payments were for

  • Food & beverage$2,207100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,207 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$46,726
Medicare patients
132
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$57,078
OzempicSemaglutide53$51,490
FarxigaDapagliflozin Propanediol31$41,601
EliquisApixaban51$40,689
JanuviaSitagliptin Phosphate37$38,337
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,550
TrulicityDulaglutide15$16,018
GemtesaVibegron18$14,515
XareltoRivaroxaban13$13,963
Tresiba Flextouch U-100Insulin Degludec12$6,324
Albuterol Sulfate HfaAlbuterol Sulfate131$3,680
Rosuvastatin Calcium148$2,648
Meclizine Hcl45$2,199
Scopolamine17$2,156
Atorvastatin Calcium293$2,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$57,07851 claims
Novo NordiskOzempic$322$51,49053 claims
AstraZenecaFarxiga$656$41,60131 claims
PfizerEliquis$212$40,68951 claims
MerckJanuvia$89$38,33737 claims
GSKTrelegy Ellipta$63$22,55021 claims
Lilly USA, LLCTrulicity$183$16,01815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Jonesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →